Lotus Pharmaceutical Becomes Strategic Partner for the Commercialization of Formycon’s Eylea® Biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region

Written by Kirsten Ruehl on 5th February 2025. Posted in Client News.